The investment in new hires for Cadran, along with January's agreement with Future Processing, to accelerate Feedback Medical's technology development and innovation, has increased the company's cost base, the principal benefit of which will not be realised until the next financial year.
Investments have been made in order to help drive sales, increase capabilities and improve functionality of Feedback's technology
Feedback PLC (LON:FDBK), the specialist medical imaging technology company, is expecting to report significant revenue growth in the current financial year.
In a short trading update covering trading in the fiscal year to 31 May, the company said the recruitment of new personnel and the investment in product sales in the first half of the financial year had given the top-line the anticipated boost but the real benefit is expected to filter through in the years to come.
In the meantime, that same investment has increased the company's cost base; as a result, the loss for the current financial year will reflect such investment but not the total anticipated income.
The strategic review of the business kicked off earlier this month by the new chief executive officer of the company, Tom Oakley, is still in progress.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Feedback PLC named herein, including the promotion by the Company of Feedback PLC in any Content on the Site, the Company receives from said...
Feedback PLC's (LON:FDBK) Tom Oakley discusses with Proactive Lonodn's Andrew Scott the upcoming commercial launch of their clinical messaging product Bleepa.
Oakley expects it to change the way medical images are communicated in everyday clinical practice on mobile devices and laptops.